Literature DB >> 2872958

Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.

J L Reid, J Vincent.   

Abstract

Prazosin is a quinazoline derivative, which lowers blood pressure by selective alpha-1-receptor antagonism. It has been found that, for similar decreases in blood pressure, prazosin causes less reflex tachycardia than non-selective alpha blockers or direct vasodilators, and that it is as efficacious as other conventional antihypertensive agents (alpha-methyldopa, hydralazine, beta blockers, etc.) in controlling severe hypertension. Prazosin causes a dose-related decrease in blood pressure in humans; twice-daily dosing is sufficient for 24-hour blood pressure control. Prazosin in combination with other drugs has also been shown to control blood pressure effectively, and it has been associated with relatively few side effects. Other agents with selective alpha-1-receptor-blocking activity are under investigation: these include doxazosin, trimazosin, terazosin, and alfuzosin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872958     DOI: 10.1159/000174002

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  7 in total

1.  Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

Authors:  Benoit Forget; Carrie Wertheim; Paola Mascia; Abhiram Pushparaj; Steven R Goldberg; Bernard Le Foll
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

2.  Acute denervation alters the epithelial response to adrenoceptor activation through an increase in alpha1-adrenoceptor expression on villus enterocytes.

Authors:  Carolyn J Baglole; David L Sigalet; Gary R Martin; Shengtao Yao; Jon B Meddings
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

3.  A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms.

Authors:  Christopher R Chapple
Journal:  Rev Urol       Date:  2005

Review 4.  Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.

Authors:  R A Young; R N Brogden
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 5.  Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents.

Authors:  K Miller
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

6.  Involvement of alpha1-adrenoceptors in conditioned place preference supported by nicotine in rats.

Authors:  Benoît Forget; Michel Hamon; Marie-Hélène Thiébot
Journal:  Psychopharmacology (Berl)       Date:  2009-05-23       Impact factor: 4.530

7.  Symptom severity impacts sympathetic dysregulation and inflammation in post-traumatic stress disorder (PTSD).

Authors:  Ida T Fonkoue; Paul J Marvar; Seth Norrholm; Yunxiao Li; Melanie L Kankam; Toure N Jones; Monica Vemulapalli; Barbara Rothbaum; J Douglas Bremner; Ngoc-Anh Le; Jeanie Park
Journal:  Brain Behav Immun       Date:  2019-11-01       Impact factor: 7.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.